Literature DB >> 3030301

Establishment of hybridoma secreting human monoclonal antibody against hepatitis B virus surface antigen.

Y Ichimori, K Harada, S Hitotsumachi, K Tsukamoto.   

Abstract

The HAT (hypoxanthine, aminopterin, thymidine) sensitive and ouabain resistant human B lymphoblastoid cell line TAW-925 was obtained from 6-thioguanine resistant B lymphoblastoid cell line WI-L2. Hybridomas were obtained at a high frequency (10(-4)-10(-5) when TAW-925 was hybridized with cells transformed with Epstein-Barr virus. Using TAW-925 as a parental cell line, we have obtained a hybridoma which stably secretes human monoclonal antibody against hepatitis B virus surface antigen.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3030301     DOI： 10.1016/0006-291x(87)91485-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  7 in total

1.  Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.

Authors:  T Sugi; T Hashimoto; T Hibi; T Nishikawa
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  Effective production of anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies by serum-free culture of hybridomas.

Authors:  K Kitano; Y Ichimori; H Sawada; S Iwasa; S Sasai; K Tsukamoto
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

3.  Comparison of culture methods for human-human hybridomas secreting anti-HBsAg human monoclonal antibodies.

Authors:  Y Shintani; Y Kohno; H Sawada; K Kitano
Journal:  Cytotechnology       Date:  1991-07       Impact factor: 2.058

4.  A human-human hybridoma secreting anti-Pseudomonas aeruginosa exotoxin-A monoclonal antibody with highly potent neutralizing activity.

Authors:  M Kuriyama; Y Ichimori; S Iwasa; K Tsukamoto
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.040

5.  A human hybrid hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by Pseudomonas aeruginosa exotoxin A.

Authors:  S Honda; Y Ichimori; S Iwasa
Journal:  Cytotechnology       Date:  1990-07       Impact factor: 2.040

Review 6.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

Review 7.  Hybridoma technology: new developments of practical interest.

Authors:  S R Samoilovich; C B Dugan; A J Macario
Journal:  J Immunol Methods       Date:  1987-08-03       Impact factor: 2.303
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.